Journal: Oncology Reports

Article Title: Dipeptidase‑2 is a prognostic marker in lung adenocarcinoma that is correlated with its sensitivity to cisplatin

doi: 10.3892/or.2023.8598

Figure Lengend Snippet: Expression levels of DPEP2 in generalized carcinoma and LUAD. (A) The heatmap of the top ten upregulated and downregulated genes with LUAD progression based on RNA sequencing data in Gene Expression Omnibus (GSE31210). (B) The expression level of DPEP2 in different tumors in TCGA was determined using TIMER2.0. (C) The cBioPortal OncoPrint map shows the distribution of DPEP2 genome changes in patients with LUAD. (D) Expression level of DPEP2 in normal tissues and tumor tissues. (E) Expression level of DPEP2 in normal tissues and the paired adjacent tumor tissues. (F) Transcriptional level of DPEP2 in the human lung bronchial epithelial cell line BEAS-2B and various LUAD cell lines (A549, H1650, and H1299). (G) Validation of the expression level of DPEP2 in LUAD using the Human Protein Atlas database (immunofluorescence). (H) The protein levels of DPEP2 were determined using western blotting in different LUAD cell lines. *P<0.05, **P<0.01 and ***P<0.001; two-tailed Student's t-test. DPEP2, dipeptidase-2; LUAD, lung adenocarcinoma.

Article Snippet: A549 (cat. no. CRL-7909; NSCLC cell line; was initiated by explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male; a hypotriploid human cell line with the modal chromosome number of 66, occurring in 24% of cells; mutations: KRAS, STK11, TP53) and H1650 (cat. no. CRL-5883; human NSCLC cell line; this was a cell line exhibiting epithelial morphology that was isolated in 1987 from the lung tissue of a 27-year-old, male smoker with stage 3B, bronchoalveolar carcinoma; mutations: EGFR, TP53) cell lines were obtained from the American Type Culture Collection.

Techniques: Expressing, RNA Sequencing, Gene Expression, Biomarker Discovery, Immunofluorescence, Western Blot, Two Tailed Test

Journal: Oncology Reports

Article Title: Dipeptidase‑2 is a prognostic marker in lung adenocarcinoma that is correlated with its sensitivity to cisplatin

doi: 10.3892/or.2023.8598

Figure Lengend Snippet: DPEP2 affects migration, invasion, and EMT of lung adenocarcinoma cells. (A) Expression of DPEP2 in empty vector control (Vector) and DPEP2-overexpressing cells (DPEP2) was detected using western blotting and reverse transcription-quantitative PCR assays. GAPDH served as a loading control. (B) Representative images and quantitative analysis of wound-healing assay of A549 and H1650 cells (scale bar, 200 µm). (C and D) Transwell representative images and analysis of (C) cell migration and (D) invasion (scale bar, 100 µm). (E and F) The EMT markers (E-cadherin, N-cadherin, vimentin, and α-SMA) were analyzed using western blot analysis and IF staining (scale bar, 50 µm). Histograms represent the mean ± standard deviation based on three independent experiments. *P<0.05, **P<0.01 and ***P<0.001, two-tailed Student's t-test. DPEP2, dipeptidase-2; EMT, epithelial-mesenchymal transition.

Article Snippet: A549 (cat. no. CRL-7909; NSCLC cell line; was initiated by explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male; a hypotriploid human cell line with the modal chromosome number of 66, occurring in 24% of cells; mutations: KRAS, STK11, TP53) and H1650 (cat. no. CRL-5883; human NSCLC cell line; this was a cell line exhibiting epithelial morphology that was isolated in 1987 from the lung tissue of a 27-year-old, male smoker with stage 3B, bronchoalveolar carcinoma; mutations: EGFR, TP53) cell lines were obtained from the American Type Culture Collection.

Techniques: Migration, Expressing, Plasmid Preparation, Control, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction, Wound Healing Assay, Staining, Standard Deviation, Two Tailed Test

Journal: Oncology Reports

Article Title: Dipeptidase‑2 is a prognostic marker in lung adenocarcinoma that is correlated with its sensitivity to cisplatin

doi: 10.3892/or.2023.8598

Figure Lengend Snippet: DPEP2 enhances lung adenocarcinoma cell sensitivity to cisplatin by regulating cancer stem cell transformation. (A and B) Expression of CD44 and CD133 was determined by western blotting and immunofluorescence staining (scale bar, 50 µm). (C) Representative images and analysis of sphere formation in A549 and H1650 cells (scale bar, 100 µm). (D) Representative images of colony formation assays of A549 and H1650 cells treated with various concentrations of cisplatin at 0, 2, 4 or 8 µg/ml. (E and F) Cell Counting Kit-8 assay was used to analyze the sensitivity of A549 and H1650 cells to various concentrations of cisplatin at 0, 2, 4 or 8 µg/ml. **P<0.01, two-way ANOVA with post hoc Dunnett's t-test. (G) Representative flow cytometric images of A549 and H1650 cells treated with 0 or 2 µg/ml cisplatin. **P<0.01 and ***P< 0.001, two-tailed Student's t-test. DPEP2, dipeptidase-2.

Article Snippet: A549 (cat. no. CRL-7909; NSCLC cell line; was initiated by explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male; a hypotriploid human cell line with the modal chromosome number of 66, occurring in 24% of cells; mutations: KRAS, STK11, TP53) and H1650 (cat. no. CRL-5883; human NSCLC cell line; this was a cell line exhibiting epithelial morphology that was isolated in 1987 from the lung tissue of a 27-year-old, male smoker with stage 3B, bronchoalveolar carcinoma; mutations: EGFR, TP53) cell lines were obtained from the American Type Culture Collection.

Techniques: Transformation Assay, Expressing, Western Blot, Immunofluorescence, Staining, Cell Counting, Two Tailed Test

Journal: Oncology Reports

Article Title: Dipeptidase‑2 is a prognostic marker in lung adenocarcinoma that is correlated with its sensitivity to cisplatin

doi: 10.3892/or.2023.8598

Figure Lengend Snippet: DPEP2 enhances the sensitivity of lung adenocarcinoma cells to cisplatin in vivo . (A) Flow chart of the in vivo experiment with nude mice. (B and C) Nude mice were subcutaneously injected with a vector or DPEP2-overexpressing A549 stable strain. On days 7 and 14, mice were injected with PBS or cisplatin (20 mg/m 2 ). Every 7 days, the tumor volume was measured with calipers. Tumor volume on day 28 was assessed using a two-tailed Student's t-test (vector vs. DPEP2; and vector + cisplatin vs. DPEP2 + cisplatin). *P<0.05 and ***P<0.001. (D and E) On day 28, tumors were excised and weighed. Representative tumors isolated from nude mice and average tumor weights. **P<0.01 and ***P<0.001, one-way ANOVA with post hoc Dunnett's t-test. (F and G) Immunohistochemical staining of DPEP2, epithelial-mesenchymal transition-associated genes (E-cadherin, N-cadherin, vimentin, and α-SMA), stem cell biomarkers (CD44 and CD133), and the proliferation marker Ki67 in tumors of mice injected with vector or DPEP2-overexpressing cells (scale bar, 100 µm). DPEP2, dipeptidase-2.

Article Snippet: A549 (cat. no. CRL-7909; NSCLC cell line; was initiated by explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male; a hypotriploid human cell line with the modal chromosome number of 66, occurring in 24% of cells; mutations: KRAS, STK11, TP53) and H1650 (cat. no. CRL-5883; human NSCLC cell line; this was a cell line exhibiting epithelial morphology that was isolated in 1987 from the lung tissue of a 27-year-old, male smoker with stage 3B, bronchoalveolar carcinoma; mutations: EGFR, TP53) cell lines were obtained from the American Type Culture Collection.

Techniques: In Vivo, Injection, Plasmid Preparation, Two Tailed Test, Isolation, Immunohistochemical staining, Staining, Marker